Scarica l'app Stockscreener
14.55
0.00%
0.00
Pre-mercato:
15.93
1.38
+9.48%
Eikon Therapeutics Inc Borsa (EIKN) Ultime notizie
Wall Street Braces For IPO Boom: Goldman Says 2026 Listings Could Hit $160 Billion As Tech, AI Lead - Benzinga
Eikon Therapeutics completes IPO and updates governance documents - The Globe and Mail
Eikon, Agomab raise $350M total in IPOs, sink in aftermarket: Public Equity Report - biocentury.com
Finance Watch: Four IPOs In One Week - Citeline News & Insights
Eikon Therapeutics, Late-Stage Clinical Oncology Drug Developer, Files for Nasdaq IPO - TradingView
Eikon Therapeutics valued at $860 million in Nasdaq debut - marketscreener.com
Eikon Therapeutics Continues the IPO Parade, Raising $381M for Cancer Drug Clinical Trials - MedCity News
Covington, Davis Polk Lead Eikon's Upsized $381M IPO - Law360
Eikon Therapeutics Shares Fall in Nasdaq Debut - marketscreener.com
Merck veteran Perlmutter-led Eikon Therapeutics valued at $860 million in Nasdaq debut - Yahoo Finance
Eikon IPO grows to biggest for biotech since 2024, raising nearly $400 million before stock falls in debut - The Business Journals
Eikon Therapeutics Opens At $17.05, IPO Priced At $18 By Investing.com - Investing.com Canada
Eikon’s $381M raise represents largest biopharma IPO in two years - BioWorld MedTech
Eikon Therapeutics, Inc. Rings the Opening Bell - Nasdaq
Perlmutter-backed Eikon Therapeutics raises $381.2 million in IPO - 1470 & 100.3 WMBD
Eikon Therapeutics raises $381M in IPO - Axios
Eikon Therapeutics nets a $381M IPO amid burst of biotech offerings - BioPharma Dive
Eikon Therapeutics prices upsized IPO at $18 per share By Investing.com - Investing.com Nigeria
Merck Veteran-Led Eikon Therapeutics Raises $381 Million in IPO - bloomberg.com
Eikon Therapeutics Announces Pricing of Upsized Initial Public Offering - Chartmill
Preview: Eikon Therapeutics, Inc Set To IPO Tomorrow - Benzinga
Eikon Therapeutics IPO: Pipeline, Technology Platform, Key Collaborations & Investment Highlights for 2026 - Minichart
Eikon aims high for NASDAQ listing: Public Equity Report - BioCentury
IPO Rating: Eikon Therapeutics, Inc. - Smartkarma
Eikon Therapeutics seeks up to $317M raise in Nasdaq IPO - BioWorld MedTech
Market Chatter: Merck Expected to Take $30 Million Stake in Eikon Therapeutics' IPO - 富途牛牛
Merck veteran-led Eikon seeks $908M valuation in US IPO - MSN
Merck (MRK) Invests in Eikon Therapeutics' IPO - GuruFocus
Merck veteran Perlmutter-led Eikon Therapeutics eyes $908 million valuation in IPO - MSN
Merck veteran Perlmutter-led Eikon ?Therapeutics eyes $908 million valuation in IPO - marketscreener.com
Eikon Therapeutics targets $317M raise in IPO - Axios
Eikon Therapeutics Eyes $908M Valuation in U.S. IPO Under Roger Perlmutter's Leadership - StockInvest.us
Merck to Acquire $30M Stake in Eikon Therapeutics - intellectia.ai
Eikon Therapeutics Launches IPO For Ambitious Oncology Pipeline Development (Pending:EIKN) - Seeking Alpha
IPOs, whale-sized fundings and an animal testing debate ahead of biotech's big JPM conference - The Business Journals
Eikon, a high-profile startup led by Merck vets, seeks an IPO - BioPharma Dive
Phase 2 biotech developing in-licensed therapies for immuno-responsive cancers. - renaissancecapital.com
Eikon Therapeutics Announces the Election of David W. Meline to its Board of Directors - Business Wire
Eikon Therapeutics to Present New Phase 2 Data on EIK1001 in First-Line Non-Small Cell Lung Cancer at ESMO 2025 - Business Wire
Eikon Therapeutics to Share Clinical Data and Program Updates at the 2025 ASCO Annual Meeting - Business Wire
Bay Area biotech company cuts 55 jobs, blames Trump-era funding reductions - San Francisco Chronicle
Eikon blames US funding cuts for 15% staff reduction centered on research tools business - Fierce Biotech
Eikon Therapeutics just raised $351 million — now it's cutting jobs thanks to Trump rollbacks - The Business Journals
In Vivo’s 2025 Rising Leaders - Citeline News & Insights
Eikon Therapeutics describes new WRN inhibitors - BioWorld MedTech
Biotech Startup Eikon Therapeutics Locks Up Massive $351M Series D - Crunchbase News
Eikon Takes TLR7/8 Agonist Into Phase III With Latest VC Mega-Round - Citeline News & Insights
Eikon Therapeutics Announces Nature Methods Publication Highlighting its Pioneering Oblique Line Scan Technology - BioSpace
Eikon Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - BioSpace
Eikon Therapeutics Appoints COO: People in the News: 11/27/24 | Business | Nov 2024 - Photonics Spectra
Eikon Therapeutics Announces Appointment of Michael Klobuchar as Chief Operating Officer - Business Wire
East Bay biotech raised about $800M in 4 years. Now it's cutting at least 10% of jobs - The Business Journals
Eikon Therapeutics advances preclinical pipeline - BioWorld MedTech
Eikon Therapeutics Announces Business Update, Highlighting Pipeline and Clinical Development Progress - Business Wire
Eikon Therapeutics bag $106m to fund eager acquisitions - Pharmaceutical Technology
Eikon Therapeutics Builds Leading Clinical Development Organization with Appointment of Senior Team with Extensive Industry Expertise - Business Wire
Eikon Therapeutics Expands Operations in New York City - Contract Pharma
Eikon Therapeutics leases Manhattan facility as East Coast base of operations - Crain's New York Business
Biotech company Eikon Therapeutics to open New York City operations base - The Business Journals
Eikon Therapeutics Signs Major Lease at New Millbrae Campus - Connect CRE
Eikon Therapeutics Announces Long-Term Lease with Alexandria Real Estate Equities, Inc. for New Corporate Headquarters in the San Francisco Bay Area - BioSpace
Eikon Therapeutics Announces the Election of Robin L. Washington to Its Board of Directors - Business Wire
Biotech company Eikon nears deal for big lease in Millbrae - The Business Journals
Eikon Therapeutics Announces the Appointment of Dr. Roy D. Baynes as Executive Vice President and Chief Medical Officer - Business Wire
Early-stage East Bay biotech headed by former Amgen, Merck R&D boss raises monster funding round - The Business Journals
Eikon Therapeutics Appoints Alfred Bowie Jr, PhD as Chief Financial Officer - Business Wire
Nobel Prize winners, all-star CEO, big bucks back East Bay biotech's deep dive into cells - The Business Journals
0.10%
7.16%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):